Clinical trials

The objective of the Global GPS Registry, including the US arm of the Global Paradise System Post Approval Study (US GPS), is to evaluate the real-world use of the Paradise System as per approved labeling. In addition, US GPS will collect data in patient populations underrepresented within the RADIANCE clinical program.

To determine the incidence and prognosis of major bleeding and vascular complications and the impact of deploying a standardized percutaneous vascular closure protocol on these endpoints.

To determine if PVI in the HFpEF population leads to effective AF burden reduction and to demonstrate feasibility in conducting a prospective single-center non-blinded randomized control trial comparing the effects of catheter ablation of AF against medical management. Feasibility is defined as both efficacy of PVI procedure in the HFpEF population in reducing the AF burden-the proportion of time the patients are in atrial fibrillation relative to total amount of recorded time-as well as the logistics involved in carrying out a single-center randomized control study involving PVI in HFpEF patients.

To assess the safety and effectiveness of the AgentTM Paclitaxel Coated PTCA Balloon Catheter compared to balloon angioplasty (POBA) in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.

This trial evaluates the effects of His or left bundle branch pacing (LBBP) comparative to biventricular pacing on quality of life, exercise capacity, hospitalization for heart failure, and mortality in patients with HF and conduction system disease.

The purpose of this study is to assess the effectivemenss of durvalumab plus tremelimumab in combination with chemotherapy complated with pembrolizumab in combination with chemotherapy (pemetrexed) in participants with metastaic lung cancer containing certain mutations. 

This study will assess the safety and efficacy of V940 in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to SOC (surgical resection with/without adjuvant RT at investigator's discretion). Participants with clinical complete response, on clinical examination and by imaging and confirmed by negative biopsy, have the option not to undergo surgery, at the investigator's discretion, and will proceed to adjuvant therapy. It is a Phase 2/3 adaptive design study, and Phase 3 expansion will be determined by prespecified Go-No-Go decision.

The purpose of this study is to compare the usual treatment to using the study drugs, Relatlimab and Nivolumab. The use of the study drugs, Relatlimab and Nivolumab, could shrink or stabilize your cancer.

The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant ± abemaciclib as compared to standard ET ± abemaciclib of patients with ER+/HER2- early breast cancer.

For participants who meet eligibility criteria to be screened for lung cancer, Inova is conducting a research project studying the cells of the nose and blood. Biomarkers (a substance in the airway and blood that is an indicator of a condition) have been identified for the early detection of lung cancer. The study is investigating if biomarkers can be used as an adjunct to screening CT scans.

While previously identified biomarkers have helped with lung cancer detection in patients with lung nodules (a small mass or lump), use of biomarkers in patients undergoing screening CT scans has not yet been determined. In this project, Inova will investigate if biomarkers from the nose or blood can help in the screening process for lung cancer. The biomarkers tests are experimental.
This study is being funded by a grant from Inova Health System.